Education
About Us
Working with TipRanks
Follow Us
Prokidney Corp. (PROK)
NASDAQ:PROK
PROK Stock Chart & Stats
$1.87
-$0.14(-7.65%)
At close: 4:00 PM EST
$1.87
-$0.14(-7.65%)
Day’s Range― - ―
52-Week Range$0.46 - $7.13
Previous CloseN/A
Volume58.77K
Average Volume (3M)1.02M
Market Cap
$562.56M
Enterprise Value$1.10B
Total Cash (Recent Filing)$271.73M
Total Debt (Recent Filing)$4.24M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding141,545,440
10 Day Avg. Volume1,106,345
30 Day Avg. Volume1,024,025
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)-0.17
Price to Sales (P/S)2177.35
P/FCF Ratio-1.06
Enterprise Value/Market Cap1.96
Enterprise Value/Revenue1.48K
Enterprise Value/Gross Profit-1.69K
Enterprise Value/Ebitda-7.38
Forecast
1Y Price Target
$5.33Price Target Upside185.03% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Accelerated Regulatory PathwayTargeting a surrogate kidney function endpoint creates a clear path for an accelerated regulatory filing that could enable earlier market approval if surrogate results meet agency standards.
Enrollment Momentum And Financial RunwayStrong patient enrollment momentum combined with reiterated cash runway supports timely study execution and allows greater focus on commercial readiness for a potential launch.
Statistical Integrity Of Pivotal TrialMaintained statistical power and preserved the planned number of confirmatory events support the trial's ability to detect meaningful treatment effects, reinforcing confidence in study validity.
Bears Say
Extended Completion Timeline RiskTargeting the same number of events with fewer total patients may slow study completion and raise uncertainty around the timing of final approval decisions.
Reduced Confirmatory EnrollmentReducing confirmatory study enrollment to about four hundred seventy patients while keeping event targets unchanged is likely to extend the time needed to reach final confirmatory results, increasing development timeline risk.
Regulatory Outcome Dependence On SurrogateReliance on achieving a specific surrogate endpoint threshold for approval creates regulatory and outcome risk if the surrogate does not meet required standards.
ProKidney News
PROK FAQ
What was Prokidney Corp.’s price range in the past 12 months?
Prokidney Corp. lowest stock price was $0.46 and its highest was $7.13 in the past 12 months.
What is Prokidney Corp.’s market cap?
Prokidney Corp.’s market cap is $562.56M.
When is Prokidney Corp.’s upcoming earnings report date?
Prokidney Corp.’s upcoming earnings report date is May 08, 2026 which is in 88 days.
How were Prokidney Corp.’s earnings last quarter?
Prokidney Corp. released its earnings results on Nov 18, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.133 by $0.013.
Is Prokidney Corp. overvalued?
According to Wall Street analysts Prokidney Corp.’s price is currently Undervalued.
Does Prokidney Corp. pay dividends?
Prokidney Corp. does not currently pay dividends.
What is Prokidney Corp.’s EPS estimate?
Prokidney Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prokidney Corp. have?
Prokidney Corp. has 141,545,440 shares outstanding.
What happened to Prokidney Corp.’s price movement after its last earnings report?
Prokidney Corp. reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.133. Following the earnings report the stock price went up 1.754%.
Which hedge fund is a major shareholder of Prokidney Corp.?
Currently, no hedge funds are holding shares in PROK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProKidney Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.33 (185.03% Upside)
$5.33 (185.03% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 17.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.94%
Trailing 12-Months
Company Description
Prokidney Corp.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$5.33
▲(185.03% Upside)
Technical Analysis
Rezolute
―
Urogen Pharma
―
Phathom Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
Currently, No data available
---